人重组蛋白 C3AR1 在脓毒症中的含量变化
摘要
月至 2019 年 3 月重庆市第四人民医院重症科室收治的 17 名脓毒症患者和 20 名脓毒性休克患者的
临床资料，包括年龄、性别、体重等，根据患者在医院的情况分为脓毒症组和脓毒性休克组，同时
选取同期于本院体检人群中 10 例作为对照组。分别检测正常组、脓毒症组和脓毒性休克组患者血
中人重组蛋白 C3AR1 的表达量。对脓毒症组和脓毒性休克组利用序贯器官衰竭评分（Sequential
Organ Failure Assessment ，SOFA）和简化急性生理学评分（simplified acute physiology score 3，SAPS3）
进行测评。结果：经过 ELISA 试剂盒检测后，对正常组、脓毒症组和脓毒性休克组患者的年龄、性
别、体重及样本情况进行统计学分析。发现脓毒症组和脓毒性休克组的人重组蛋白 C3AR1 的表达
量都高于正常组，且脓毒性休克组的 C3AR1 的表达量远高于脓毒症组。脓毒性休克组的 SOFA 评
分和 SAPS3 评分都高于脓毒症组，说明脓毒性休克组的预后相比较差。结论：人重组蛋白 C3AR1
的表达量会随着脓毒症病情的严重程度而呈现出有规律的变化趋势，可以将人重组蛋白 C3AR1 认
定为脓毒症的标志性化合物。
关键词
参考
[1]任清竹,苏和,张瑞芬,等.脓毒症的病因病
机 及 中 药 治 疗 研 究 进 展 [J]. 内 蒙 古 中 医
药,2022,41(04):167-168. [2]Xie J, Wang H, Kang Y, et al. The
epidemiology of sepsis in Chinese ICUs:A
national cross-sectional survey[J].Crit Care
Med ,2020 ,48(3) :209-218. [3]田慈，谢苗荣.脓毒症心肌损伤机制的研
发 进 展 [J]. 临 床 和 实 验 医 学 杂 志 ， 2013,12
（2）:148-150. [4]Weng L,Zeng XY,Yin PC,et al.Sepsis-re
lated mortaliti in China:a descriptive analysis[J]. Itennsive Care Med,2018,44(7):1071-1080. [5]颜青. C3AR1基因促进HL60细胞迁移侵
袭及耐药机制研究[D].苏州大学,2016. [6][1] Drouin S M , Kildsgaard J , Haviland J ,
et al. Expression of the Complement Anaphylatoxin
C3a and C5a Receptors on Bronchial Epithelial and
Smooth Muscle Cells in Models of Sepsis and
Asthma[J]. Journal of Immunology, 2001, 166(3):2025-2032. [7]Sacks SH.Complement fragments C3a and
C5a: the salt and pepper of the immune response[J]. EurJ Immunol,2010,40(3):668-670. [8]郭润静,郝东.脓毒症相关生物标志物及
作用机制研究进展[J].国际医药卫生导报,2022, 28(10):1468-1471. [9] Rello J, Valenzuela-Sanche F, Ruiz-Rod
riguez M, et al. Sepsis: a review of advances
in management[J]. Adv Ther, 2017,34(11):2393. [10]Cecconi M, Evans L, Levy M, et al. Sepsis
and septic shock[J]. Lancet, 2018,392(10141):75. [11]Spoto S,Cella E,Cesaris M D, et
al.Procalcitonin and MR-Proadrenomedullin
combination with SOFA and qSOFA scores for
sepsis diagnosis and prognosis:a diagnostic
algorithm[J].Shock,2018,50(1):44-52. [12]查君敬,方长太,白兆青,等.白细胞介素 3
5、降钙素原及 SOFA 评分对脓毒症病情严重程
度及预后的评判价值[J].重庆医学,2019,48(09):
1535-1538. [13] Schuetz P, Marlowe RJ, Mueller B. The
prognostic blood biomarker proadrenomedullin for
outcome prediction in patients with chronic
obstructive pulmonary disease(COPD):a
qualitative clinical review[J].Clin Chem Lab Med, 2015, 53(4):521-539. [14] Covington EW, Roberts MZ, Dong J. Procalcitonin monitoring as a guide for antimicrobial
therapy: a review of current literature[J]. Pharmacotherapy,2018, 38(5): 569-581. [15] Semeraro F, Ammollo CT, Caironi P, et
al. D-dimer correctde for thrombin and plasmin
generation is a strong predictor of mortality in
patients with sepsis[J]. Blood Transfus, 2020, 18(4): 304-311. [16] Hegazy MA，Omar AS，Samir N，et
al ． Amalgamation of procalcitonin ， C-reactive
protein ， and sequential organ failure scoring
system in predicting sepsis survival[J]． Anesth
Essays Res，2014，8 ( 3 ) : 296-301．
[17] JainA，Palta S，Saroa R，et al．Sequential
organ failure assessment scoring and prediction of
patient's outcome in Intensive Care Unit of a tertiary
care hospital[J]． J Anaesthesiol Clin Pharmacol，
2016，32( 3) : 364-368．
[18] Raith EP ， Udy AA ， Bailey M ， et
al． Prognostic Accuracy of the SOFA Score，
SI Ｒ S Criteria ， and qSOFA Score for In －
Hospital Mortality Among Adults With Suspected
Infection Admitted to the Intensive Care
Unit[J]．JAMA，2017，317( 3) : 290-300．
[19]王力鹏,陈军,罗穆玲,等.MEWS 评分、A
PACHE Ⅱ评分及SOFA评分对急诊重症患者死
亡风险的评价[J].广东医学,2018,39(06):893-896. [20]Kartal ED ， Karkac E ， Gulbas Z ， et
al． Several cytokines and protein C levels with
the APACHE Ⅱ scoring system for evaluation of
patients with sepsis[J]． Balkan Med J，2012，29
(2) : 174-178．
[21] 杨旭，刘志．联合应用早期体温峰值
及 48h - ΔSOFA 评分对急诊脓毒症患者预后评
估的临床价值[J]． 中华急诊医学杂志，2016，
25 ( 1) : 68-72．
[22]Soares M, Salluh JI, Validation of the
SAPS3 admission prognostic model in patients
with cancer in need of intensive care[J]. Intensive
Care Med, 2006, 32: 1839-1844. [23]陈珊珊,曹霖,汪晓东,等.急性简化生理
学评分Ⅲ的应用现状[J].中国呼吸与危重监护杂
志,2009,8(02):202-206. [24] Rogli A , Prossnitz E R , Cavanagh
S L , et al. cDNA cloning of a novel G prote
in-coupled receptor with a large extracellular
loop structure[J]. Biochimica et Biophysica Act
a,1996, 1305(1-2):39-43. [25] Halova, I,Draberova L, and Draber
P.Mast cell chemotaxis - chemoattractants and
signaling pathways[J]. Front Immunol, 2012, 3:
119. [26] Sim, R.B. and A. Laich. Serine proteases
of the complement system[J]. Biochem Soc Trans, 2000. 28(5): 545-550. [27] Marc M M , Korosec P , Kosnik M , et al. Complement factors c3a, c4a, and c5a in
chronic obstructive pulmonary disease and
asthma.[J]. Am J Respir Cell Mol Biol, 2004, 31(2):216-219. [28] Sacks SH, Complement fragments C3a
and C5a: the salt and pepper of the
immuneC3AR1 response[J]. Eur J Immunol, 2010. 40(3): p. 668-70. [29]Mizuno M , Blanchin S , Gasque P , et al. High levels of complement C3a receptor in
the glomeruli in lupus nephritis.[J]. American
Journal of Kidney Diseases the Official Journal of
the National Kidney Foundation, 2007, 49(5):598-606. [30] Drouin S M , Kildsgaard J , Haviland J , et al. Expression of the Complement Anaphylatoxin
C3a and C5a Receptors on Bronchial Epithelial and
Smooth Muscle Cells in Models of Sepsis and
Asthma[J]. Journal of Immunology, 2001, 166(3):2025-2032. [31] Oksjoki R , Laine P , Helske S , et al. Receptors for the anaphylatoxins C3a and C5a are
expressed in human atherosclerotic coronary
plaques[J]. Atherosclerosis, 2007, 195(1):90-99. [32]颜青,李争,岑建农,等.过表达 C3AR1 基
因促进 HL-60 细胞迁移和侵袭[J].中国实验血液
学杂志,2017,25(01):1-7.
[33]Wu SY, Fan J, Hong D, et al. C3ARl gene
overexpressed at initial stage of acute myeloid
leukemia-M2 predicting short-term survival[J]. Leukemia Lymphoma, 2015; 56(7): 2200-2202.
Refbacks
- 当前没有refback。